Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activityChaolin Huang(Wenzhou Medical University), Qiaoxiang Dong(Wenzhou Medical University)OncotargetDecember 14, 201710.18632/oncotarget.23250Cited by 60SaveCiteExport RISWatch citationsRelated PapersAging is associated with an expansion of CD49fhi mammary stem cells that show a decline in function and increased transformation potential|Aging|2016|35